Eversept Partners LP Takes $6.33 Million Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Eversept Partners LP purchased a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 19,049 shares of the company's stock, valued at approximately $6,329,000. Eversept Partners LP owned about 0.06% of Medpace at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of MEDP. R Squared Ltd acquired a new position in shares of Medpace during the 4th quarter worth approximately $30,000. SBI Securities Co. Ltd. purchased a new position in Medpace during the fourth quarter worth approximately $31,000. Jones Financial Companies Lllp boosted its stake in Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company's stock worth $38,000 after buying an additional 110 shares during the last quarter. Lindbrook Capital LLC grew its holdings in Medpace by 27.6% in the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company's stock valued at $45,000 after buying an additional 29 shares in the last quarter. Finally, Assetmark Inc. increased its stake in shares of Medpace by 20.1% in the 4th quarter. Assetmark Inc. now owns 173 shares of the company's stock worth $57,000 after acquiring an additional 29 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on the stock. TD Cowen cut shares of Medpace from a "buy" rating to a "hold" rating and lowered their price target for the company from $370.00 to $328.00 in a research report on Monday, April 14th. Robert W. Baird decreased their target price on shares of Medpace from $340.00 to $313.00 and set a "neutral" rating on the stock in a report on Wednesday. Mizuho cut their price target on shares of Medpace from $400.00 to $355.00 and set an "outperform" rating for the company in a report on Wednesday, April 9th. Leerink Partners began coverage on Medpace in a report on Monday, March 24th. They issued a "market perform" rating and a $330.00 price objective on the stock. Finally, Leerink Partnrs upgraded Medpace to a "hold" rating in a research report on Monday, March 24th. Eleven investment analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus price target of $349.30.

Medpace Price Performance

Shares of MEDP stock traded down $4.33 on Friday, hitting $298.55. The stock had a trading volume of 399,606 shares, compared to its average volume of 339,939. The company's 50 day moving average price is $313.79 and its 200-day moving average price is $331.60. Medpace Holdings, Inc. has a 1 year low of $250.05 and a 1 year high of $459.77. The firm has a market capitalization of $9.02 billion, a P/E ratio of 23.64, a P/E/G ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP - Get Free Report) last issued its quarterly earnings results on Monday, April 21st. The company reported $3.67 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.06 by $0.61. Medpace had a net margin of 19.17% and a return on equity of 51.48%. The company had revenue of $558.57 million for the quarter, compared to analyst estimates of $528.38 million. During the same period in the prior year, the firm earned $3.20 earnings per share. On average, equities analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.